Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 9.50
Ask: 11.00
Change: 0.00 (0.00%)
Spread: 1.50 (15.789%)
Open: 10.25
High: 10.40
Low: 10.00
Prev. Close: 10.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Scancell Holdings Suspends Dosing In SCIB1 Cancer Treatment Trials

Fri, 17th Jun 2016 06:44

LONDON (Alliance News) - Cancer immuotherapies developer Scancell Holdings PLC on Friday said it has suspended dosing with its current clinical trial supplies for its SCIB1 treatment with immediate effect.

Scancell said ongoing quality control analysis has found the stored drug product no longer meets the original specifications for the trial and has concluded it is no longer suitable for further use. No side effects from the use of the drug have emerged, Scancell said.

The suspension will effect eight patients in the trial, which is investigating the use of SCIB1 as a monotherapy for the treatment of melanoma.

Scancell said it intends to make a fresh batch of SCIB1 and has recently signed an agreement with a manufacturer.

"Patient safety has always been our primary responsibility. Although we have seen no new adverse events it is unfortunate, but nevertheless appropriate, that we suspend dosing of SCIB1 at this time while we work as quickly as possible to secure new supplies of this promising potential treatment for melanoma," said Scancell Chief Executive Richard Goodfellow.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
20 Oct 2015 07:48

Scancell Expects SCIB1 Clinical Study Report In First Half Of 2016

Read more
13 Oct 2015 15:22

AGM, EGM Calendar - Week Ahead

Read more
18 Sep 2015 09:23

Bigger loss but positive drug trial results for Scancell Holdings

(ShareCast News) - Scancell Holdings's losses increased marginally in the year ended 30 April 2015. The cancer immunotherapy developer announced on Friday a wider loss of £2.414m from £2.222m last year. It comes as a result of expected additional expenditure on its SCIB1 ImmunoBody clinical trials

Read more
18 Sep 2015 07:49

Scancell Holdings Loss Wider On Higher Development Costs

Read more
30 Jul 2015 09:40

Scancell Signs Research Collaboration Deal With ImmunID

Read more
9 Jul 2015 08:57

Scancell Closes Patient Recruitment For Next Phase Of SCIB1 Trials

Read more
2 Jun 2015 12:19

Scancell gives positive update on melanoma treatment data

Biopharmaceutical company Scancell Holdings reported further encouraging results from the ongoing 'Phase 1/2' clinical trial of its melanoma treatment SCIB1, which it presented at the annual meeting of the American Society of Clinical Oncology in Chicago. The data showed that all 16 patients with re

Read more
2 Jun 2015 07:27

Scancell Reports Encouraging Ongoing SCIB1Trial Results

Read more
24 Mar 2015 10:21

Scancell Says New Data Supports SCIB2 Combination Treatment

Read more
12 Jan 2015 09:47

Scancell Sees Positive Data In On-Going Phase I/2 SCIB1Trial

Read more
14 Oct 2014 11:23

UK MIDDAY BRIEFING: Life's No Catwalk For Luxury Goods Makers

Read more
14 Oct 2014 11:09

UK WINNERS & LOSERS: Miners Continue Run, Oil Companies Fall

Read more
14 Oct 2014 07:44

Scancell Shares Boosted By Positive SCIB-1 Trial Results

Read more
14 Oct 2014 07:32

UK MORNING BRIEFING: Burberry And Hargreaves Lansdown Lead Declines

Read more
14 Oct 2014 05:22

UK AGM, EGM Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.